Newsroom

NEW YORK--(BUSINESS WIRE)--CohnReznick, a leading professional services firm, today announced a strategic acquisition of Minneapolis, MN-based Smith Schafer & Associates, effective January 1, 2026. With three offices in the market, Smith Schafer’s local expertise establishes an important expansion in the Midwest for CohnReznick and significant growth opportunity for the combined organization. With a team of 12 partners and 89 employees, Smith Schafer brings to CohnReznick strong experience...

PASADENA, Calif.--(BUSINESS WIRE)--Applebee’s is kicking the year off with the return of $6 Mucho Smoocho Sips. Beginning today, love is in the air – and in Applebee’s $6 Mucho cocktails – including the fan-favorite Tipsy Cupid and NEW Prickly Ever After Rita.* Plus, guests who are looking for a spark to share with that special someone - with a different kind of buzz - can enjoy the NEW Prickly Melon Rush Mocktail. Celebrate date night, Galentine’s Day, or a night out with friends with the Tips...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust FactorFX UCITS ETF 02.01.2026 FXGB LN IE00BD5HBR05 37,992.00 GBP 741,417.71 26.345  ...

NEW YORK--(BUSINESS WIRE)--BNB Plus Corp. (Nasdaq: BNBX) (“BNBX” or the “Company”), today announced that it has received a $1.2M USD order for LineaDNA, representing the largest LineaDNA order in Company history. The order is an acceleration of an existing customer's annual purchasing cadence, consolidating what was originally planned as a two-year order cycle into an accelerated delivery schedule expected to be completed by May 2026. The order was placed by a global manufacturer of in vitro di...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Dow Jones Internet UCITS ETF 02.01.2026 FDNU IE00BG0SSC32 2,325,002.00 USD 85,293,247.41 36.685  ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Star Therapeutics, a late clinical-stage biotechnology company discovering and developing best-in-class antibodies for bleeding disorders and other diseases, today announced that Adam Rosenthal, Ph.D., CEO and Founder, will present at the 44th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026, at 4:30 p.m. PT in San Francisco, CA. Dr. Rosenthal will provide an overview of the company and its lead program, VGA039, a first-in-class...

NEWTON, Mass.--(BUSINESS WIRE)--Diversified Healthcare Trust (Nasdaq: DHC) (“DHC”) today provided a business update regarding its capital recycling program, the full repayment of its 2026 zero coupon bonds and the transition of operations of its senior housing operating portfolio (“SHOP”) communities from AlerisLife Inc. to new operators. Property Sales Update DHC continues to advance its previously disclosed capital recycling program focused on the sale of non-core properties. During the fourt...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced that David J. Earp, J.D., Ph.D., president and chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 at 5:00 p.m. PT. Dr. Earp will provide an overview of the company’s pipeline, including CID-078, a first-in-class oral macrocyclic c...

CHICAGO--(BUSINESS WIRE)--Morningstar, Inc. (Nasdaq: MORN), a leading provider of independent investment insights, today announced that Anne Bramman has been elected to Morningstar’s board of directors. Bramman currently serves as a board director and audit committee chair at McCormick & Company and as a senior advisor at Boston Consulting Group. Prior to her current board and advisory roles, Bramman held senior leadership positions as CFO for several global companies including Nordstrom, A...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Marea Therapeutics, Inc., a clinical-stage biotechnology company harnessing the latest advances in human genetics to develop first-in-class, next-generation medicines for cardioendocrine diseases, today announced that Josh Lehrer, M.D., chief executive officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Tuesday, January 13, 2026 at 10:30 a.m. PT. Dr. Lehrer will provide an overview of Marea’s pipeline, including MAR001 a fi...